Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 8von Hippel-Lindau Disease 3Pheochromocytoma 2Paraganglioma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Kidney Neoplasms 1Hemangioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Cisplatin 22pembrolizumab 21Carboplatin 12Radiotherapy 11Paclitaxel 11Brachytherapy 11Drug Therapy 10Bevacizumab 9Blood Specimen Collection 7Colposcopy 6Specimen Handling 5Injections 5toripalimab 4Taxes 4Surveys and Questionnaires 4Nivolumab 4Mass Screening 4Human Papillomavirus DNA Tests 4Gemcitabine 4Chemotherapy, Adjuvant 4Chemoradiotherapy 4spartalizumab 3lenvatinib 3camrelizumab 3aldesleukin 3Restraint, Physical 3Radiation 3Fulvestrant 3Cyclophosphamide 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Cervical Neoplasms × belzutifan × Clear all
NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡